Clinical trials: SGLT2-Inhibitors
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Coronary Syndrome, Atrial Fibrillation
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
The goal of this randomized, double-blinded, controlled clinical trial is to investigate if treatment with an sodium-glucose cotransporter-2 inhibitor (SGLT2) during the unique time window before coronary artery bypass surgery…
- Trial name
- STENOTYPE (NCT05852704)
- Testing
- Dapagliflozin 10mg Tab
- Where
- 8 sites in Czechia, Denmark and 1 more
- Volunteers
- 800 people
- Sponsor
- Region Örebro County
Type2 Diabetes Mellitus
Study to Develop a Kinetic Model for FDG and Me4FDG in Kidneys of Type 2 Diabetic Patients
In this study, using 18F-FDG and Gd-DTPA PET/MRI, we are aiming to perform a dynamic PET/MRI imaging using 18F-FDG and Me4FDG for a group of type 2 diabetic patients scheduled for Glifozine therapy due to the bad metabolic…
- Trial name
- NCT03557138
- Testing
- alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Metabolic Disease, Diabetes
The Triglyceride/Glucose Index and SGLT-2 Inhibitors
This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and…
- Trial name
- NCT05915884
- Testing
- SGLT-2 inhibitors
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- Samsun Education and Research Hospital
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Diabetes Mellitus, Type 2
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: 60 patients…
- Trial name
- NCT03878706
- Where
- Greece
- Volunteers
- 240 people
- Sponsor
- University of Athens
Overweight, Carbohydrate
Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.
In recent years, the prevalence of overweight and obesity has increased dramatically worldwide, of which 34.3% and 16.4% of adults in China are overweight and obese, respectively, ranking first in the world's obese population.
- Conditions
- Overweight, Carbohydrate, Sodium-glucose Transporter 2 Inhibitors
- Trial name
- NCT06383832
- Testing
- Dapagliflozin
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Sun Jia
Sepsis, Septic Shock
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT06902493
- Testing
- No intervention
- Where
- Saudi Arabia
- Volunteers
- 664 people
- Sponsor
- University of Jazan
Chronic Heart Failure
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
The hypothesis is that the SGLT-2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure, and if the hypothesis is proven, that this mechanism contributes to the beneficial effects found in…
- Trial name
- ELSI (NCT03128528)
- Testing
- Empagliflozin 10mg
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Obesity and Type 2 Diabetes
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise…
- Trial name
- ENVY (NCT06782139)
- Testing
- Enavogliflozin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Korea University Anam Hospital
Type1diabetes
Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin
One of the challenges in the design of the artificial pancreas (AP) is preventing postprandial hyperglycemia. Beyond algorithmic solutions, one countermeasure to postprandial hyperglycemia that may enhance performance of the AP…
- Trial name
- CLASS15 (NCT03510000)
- Testing
- Empagliflozin 25mg, Single hormone artificial pancreas, Meal strategies
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Type 2 Diabetes Mellitus, Hypertension
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
This randomized controlled trial studied whether empagliflozin lowers blood pressure better than non-SGLT2 oral hypoglycemic treatment in adults with type 2 diabetes mellitus and hypertension.
- Trial name
- EMPA-BP (NCT07541456)
- Testing
- Empagliflozin, Metformin
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Dr. Zarmina Younes
Hypertension (HTN)
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with…
- Trial name
- NCT07678151
- Testing
- Empagliflozin and Finerenone
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Heart Health Research Center
Type 1 Diabetes, Nephropathy, Diabetic
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Trial name
- NCT07591077
- Testing
- Empagliflozin (EMPA)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Ain Shams University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease, Atherosclerosis
- Trial name
- SCOPE (NCT07614230)
- Testing
- Dapagliflozin (DAPA), Standard Care (Treatment as Usual)
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Junjie Yang
SGLT2 Inhibitor, Ketoacidosis, Eugylcemic
Incidence, Characterisation and Outcome-relevance of Perioperative SGLT2 Inhibitor Associated Ketoacidosis
The goal of this observational study is to generate data on the incidence and outcome-relevance of sodium-glucose cotransporter 2 (SGLT2) inhibitor associated ketoacidosis in adult patients with regular intake of any SGLT2…
- Trial name
- NCT06838507
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Postprandial Hypoglycemia
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.
- Trial name
- Hypo-PrEA (NCT05174507)
- Testing
- empagliflozin, anakinra
- Sponsor
- University Hospital, Basel, Switzerland
Rheumatoid Arthritis (RA)
Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis
This study aims to evaluate the efficacy and safety of dapagliflozin and empagliflozin as adjunctive therapies to methotrexate in patients with rheumatoid arthritis who have active disease despite stable methotrexate treatment.
- Trial name
- NCT07864688
- Testing
- Dapagliflozin, Empagliflozin, Methotrexate
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Al-Azhar University
End Stage Renal Disease
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
- Trial name
- NCT03713190
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Pisa